Loading
Hemoglobinopathies and Related Disorders / CRISPR and Genetic Engineering · Review
Epidemiology and Health Data Insights · August 30, 2026
Reinforces what was already believed, rather than introducing something new.
This systematic review synthesizes evidence on CRISPR-Cas9 applications in sickle cell disease and malaria research across 13 studies. It confirms clinical progress in SCD gene therapy using edited haematopoietic stem cells, while malaria applications remain experimental. No study demonstrated dual therapeutic benefit for both conditions.
Systematic review following PRISMA 2020 and Joanna Briggs Institute guidance. Studies investigating CRISPR-Cas9 applications related to SCD or malaria across any study design and setting.. Intervention: CRISPR-Cas9 gene editing applications including HBB correction, fetal haemoglobin induction, host-cell modification, parasite genome editing and mosquito-vector modification.
Thirteen studies included: six SCD-related and seven malaria-related studies SCD studies demonstrated progression from experimental genome correction to clinical application of CRISPR-edited autologous haematopoietic stem and progenitor cells Malaria-related studies primarily investigated parasite functional genomics, erythrocyte invasion mechanisms and mosquito genetic modification
SCD clinical evidence limited to application of edited autologous cells; long-term durability and safety data not detailed
Clinicians should recognise that CRISPR-Cas9 has established translational pathways in SCD with clinical applications, but malaria-focused CRISPR research remains experimental. No single intervention addresses both conditions simultaneously.
A systematic review synthesizing existing literature on CRISPR-Cas9 applications in two distinct disease areas, confirming established preclinical and early clinical evidence without reporting novel primary data or practice-changing findings.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognise that CRISPR-Cas9 has established translational pathways in SCD with clinical applications, but malaria-focused CRISPR research remains experimental. No single intervention addresses both conditions simultaneously.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: Sickle cell disease (SCD) and malaria remain major health challenges in sub-Saharan Africa. CRISPR-Cas9 has enabled advances in SCD gene therapy and malaria-related experimental research, but these applications represent distinct biological and translational pathways. This systematic review evaluated CRISPR-Cas9 applications in SCD and malaria research while distinguishing clinical therapeutic evidence from experimental malaria-related findings. Methods: A systematic review was conducted following PRISMA 2020 and Joanna Briggs Institute guidance. PubMed, ScienceDirect and Google Scholar were searched on 12 August 2026. Studies investigating CRISPR-Cas9 applications related to SCD or malaria, including HBBcorrection, fetal haemoglobin induction, host-cell modification, parasite genome editing and mosquito-vector modification, were included. Data were synthesised narratively due to substantial heterogeneity among study designs and outcomes. Results: Thirteen studies were included, comprising six SCD-related and seven malaria-related studies. SCD studies demonstrated progression from experimental genome correction and haemoglobin regulation strategies to clinical application of CRISPR-edited autologous haematopoietic stem and progenitor cells. Malaria-related studies primarily investigated parasite functional genomics, erythrocyte invasion mechanisms and mosquito genetic modification. No included study evaluated a single CRISPR-Cas9 intervention that simultaneously treated SCD and enhanced malaria resistance. Conclusion: CRISPR-Cas9 represents an advancing therapeutic platform for selected SCD applications and an important experimental tool in malaria research. Current evidence supports separate translational pathways, with clinical progress established in SCD and malaria applications remaining predominantly preclinical.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.